|
|
Volumn 10, Issue 6, 2004, Pages 551-554
|
|
Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
ISOENZYME;
LACTONE;
MEMBRANE PROTEIN;
PROSTAGLANDIN SYNTHASE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
PTGS2 PROTEIN, HUMAN;
ROFECOXIB;
SULFONE;
CARDIOVASCULAR DISEASE;
CHEMICALLY INDUCED DISORDER;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
UNITED STATES;
CARDIOVASCULAR DISEASES;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITORS;
CYCLOOXYGENASE INHIBITORS;
HUMANS;
ISOENZYMES;
LACTONES;
MEMBRANE PROTEINS;
PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;
SULFONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
MLCS;
MLOWN;
|
|
EID: 16644377516
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: 10.18553/jmcp.2004.10.6.551 Document Type: Editorial |
|
Times cited : (26)
|
|
References (0)
|
